Lv1
36 积分 2022-09-30 加入
Postoperative hepatic insufficiency despite preoperative portal vein embolization: Not just about the volumetrics
2天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
1个月前
已完结
Remain recipient partial liver during liver transplant after Hassab
2个月前
已完结
The roles of transient receptor potential vanilloid in autoimmune diseases
2个月前
已完结
Cholangiocarcinoma
2个月前
已完结
Intrahepatic cholangiocarcinoma: Limitations for resectability, current surgical concepts and future perspectives
2个月前
已完结
A GOLP rush in biliary tract cancer: early promise in the quest for curative surgery
3个月前
已完结
THU-095 Single-cell spatial proteomic landscape of intrahepatic cholangiocarcinoma immune microenvironment reveals immune evasion via FSTL1negative macrophage
3个月前
已关闭
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
4个月前
已完结
皖公网安备34019202002308
